Very encouraging RNS2 Mar 2021 07:08
Dr Anne Brindley, CEO of Nuformix, said: "IPF is a devastating disease with few treatment options and there is a real need for new therapies that are efficacious but that have better tolerability than the current therapies on the market. IPF is likely to become a combination market in the future. The results of this ex-vivo study in IPF are very encouraging and suggest the potential benefit of using NXP002 in combination with standard of care treatments for IPF. These results underpin NXP002's potential and demonstrate that further development of NXP002 for the treatment of IPF is warranted."